News | January 06, 2023
Chindex Medical acquires 10 ViewRay MRIdian Systems for advanced cancer treatment
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
This ambitious anti-TB campaign, as part of IOCL’s CSR, aims to ensure early identification of presumptive TB and prompt diagnosis using high-sensitivity diagnostic tests at the doorstep
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
The organisation is also working towards providing skills based training programmes to the workers for paramedical jobs and has launched certificate courses in ten disciplines
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
It offers quick relief in various types of Coughs, Colds and Sore Throat,
The Group will continue to make proactive investments of its management resources in the life science business
Revenue is up 23% whereas Profit After Tax expands 29% for the company
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
Subscribe To Our Newsletter & Stay Updated
